Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Multivalent Vaccines for Rabies Virus and Coronaviruses, 49599 [2022-17214]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 154 / Thursday, August 11, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License, Inter-Institutional AgreementInstitution Lead: Multivalent Vaccines
for Rabies Virus and Coronaviruses
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive, sublicensable
patent license to Thomas Jefferson
University, located in Philadelphia,
Pennsylvania to practice the inventions
embodied in the patent applications
listed in the Supplementary Information
section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
and Intellectual Property Office,
National Institute of Allergy and
Infectious Diseases on or before August
26, 2022 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Wade Green, Ph.D., Lead
Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases (NIAID), 5601 Fishers Lane,
Suite 6D, MSC9804, Rockville, MD
20852–9804, phone number 301–761–
7505, or wade.green@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: US Provisional
Patent Application Number 62/318,087,
filed 04 April 2016, titled ‘‘Multivalent
vaccines for rabies virus and
coronaviruses’’ (HHS Reference No. E–
128–2016–0–US–01); PCT Application
Number PCT/US17/25623, filed 31
March 2017, titled ‘‘Multivalent
vaccines for rabies virus and
coronaviruses’’ (HHS Reference No. E–
128–2016–0–PCT–02); US Patent
11,041,170, issued 22 June 2021, titled
‘‘Multivalent vaccines for rabies virus
and coronaviruses’’ (HHS Reference No.
E–128–2016–0–US–05); US Patent
Application Number 17/307,066, filed
04 May 2021, titled ‘‘Multivalent
vaccines for rabies virus and
coronaviruses’’ (HHS Reference No. E–
128–2016–0–US–06); EPO Patent
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:49 Aug 10, 2022
Jkt 256001
Application Number 2017718216.9,
filed 31 March 2017, titled ‘‘Multivalent
vaccines for rabies virus and
coronaviruses’’ (HHS Reference No. E–
128–2016–0–EP–03); and Saudi Arabian
Patent Application Number 518400172,
filed 04 October 2018, titled
‘‘Multivalent vaccines for rabies virus
and coronaviruses’’ (HHS Reference No.
E–128–2016–0–SA–04). All rights in
these inventions have been assigned to
Thomas Jefferson University, University
of Maryland, Baltimore, and the
Government of the United States of
America as represented by the
Secretary, Department of Health &
Human Services.
The prospective patent license will be
for the purpose of consolidating the
patent rights to Thomas Jefferson
University, one of the co-owners of said
rights, for commercial development and
marketing.
Consolidation of these co-owned
rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective interinstitutional
agreement will include an exclusive
license for NIAID’s rights in these
jointly owned patents. It will be
sublicensable, and any sublicenses
granted by Thomas Jefferson University
will be subject to the provisions of 37
CFR part 401 and 404.
The subject patent rights are related to
novel recombinant vaccine constructs
based on a genetically modified,
attenuated rabies virus vaccine vector
expressing one or more coronavirus
immunogenic polypeptides. These
constructs elicit strong bi-valent
immunogenic responses against both
rabies virus and the respective
coronavirus in animal models. The
novel rabies virus vector used in these
constructs was developed by Thomas
Jefferson University prior to the codevelopment of the subject patent rights
by Thomas Jefferson University, the
University of Maryland, Baltimore, and
NIAID.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Insitute of Allergy and
Infectious Diseases receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
49599
application, will not be treated
confidentially, and may be made
publicly available.
Complete license applications
submitted in response to this Notice
will be presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: August 5, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2022–17214 Filed 8–10–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2022–0259]
Safe Loading, Safe Powering and
Flotation Compliance Guidance for
Electrically Powered Recreational
Vessels Policy Letter
Coast Guard, DHS.
Notice of availability and
request for comments.
AGENCY:
ACTION:
The Coast Guard announces
the online availability, of a new Coast
Guard policy that establishes regulatory
compliance guidance for recreational
vessels less than 20 feet in length that
use batteries to power their primary
propulsion. This document provides
consistent guidance for the design,
inspection, and/or testing of recreational
vessels using batteries to power their
primary propulsion. The policy can be
found at https://safeafloat.com/policiesletters/.
DATES: Comments must be submitted to
the online docket via https://
www.regulations.gov on or before
November 9, 2022.
ADDRESSES: You may submit comments
identified by docket number USCG–
2022–0259 using the Federal
eRulemaking Portal at https://
www.regulations.gov. See the ‘‘Public
Participation and Request for
Comments’’ portion of the
SUPPLEMENTARY INFORMATION section for
further instructions on submitting
comments.
FOR FURTHER INFORMATION CONTACT: For
information about this document call or
email Mr. Kevin Ferrie, Coast Guard;
telephone 202–372–1075, email
kevin.b.ferrie@uscg.mil.
SUMMARY:
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 87, Number 154 (Thursday, August 11, 2022)]
[Notices]
[Page 49599]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17214]
[[Page 49599]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Multivalent Vaccines for Rabies Virus and
Coronaviruses
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive,
sublicensable patent license to Thomas Jefferson University, located in
Philadelphia, Pennsylvania to practice the inventions embodied in the
patent applications listed in the Supplementary Information section of
this notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before August 26, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and
Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases (NIAID),
5601 Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804, phone
number 301-761-7505, or [email protected].
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: US Provisional
Patent Application Number 62/318,087, filed 04 April 2016, titled
``Multivalent vaccines for rabies virus and coronaviruses'' (HHS
Reference No. E-128-2016-0-US-01); PCT Application Number PCT/US17/
25623, filed 31 March 2017, titled ``Multivalent vaccines for rabies
virus and coronaviruses'' (HHS Reference No. E-128-2016-0-PCT-02); US
Patent 11,041,170, issued 22 June 2021, titled ``Multivalent vaccines
for rabies virus and coronaviruses'' (HHS Reference No. E-128-2016-0-
US-05); US Patent Application Number 17/307,066, filed 04 May 2021,
titled ``Multivalent vaccines for rabies virus and coronaviruses'' (HHS
Reference No. E-128-2016-0-US-06); EPO Patent Application Number
2017718216.9, filed 31 March 2017, titled ``Multivalent vaccines for
rabies virus and coronaviruses'' (HHS Reference No. E-128-2016-0-EP-
03); and Saudi Arabian Patent Application Number 518400172, filed 04
October 2018, titled ``Multivalent vaccines for rabies virus and
coronaviruses'' (HHS Reference No. E-128-2016-0-SA-04). All rights in
these inventions have been assigned to Thomas Jefferson University,
University of Maryland, Baltimore, and the Government of the United
States of America as represented by the Secretary, Department of Health
& Human Services.
The prospective patent license will be for the purpose of
consolidating the patent rights to Thomas Jefferson University, one of
the co-owners of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective interinstitutional agreement will include an
exclusive license for NIAID's rights in these jointly owned patents. It
will be sublicensable, and any sublicenses granted by Thomas Jefferson
University will be subject to the provisions of 37 CFR part 401 and
404.
The subject patent rights are related to novel recombinant vaccine
constructs based on a genetically modified, attenuated rabies virus
vaccine vector expressing one or more coronavirus immunogenic
polypeptides. These constructs elicit strong bi-valent immunogenic
responses against both rabies virus and the respective coronavirus in
animal models. The novel rabies virus vector used in these constructs
was developed by Thomas Jefferson University prior to the co-
development of the subject patent rights by Thomas Jefferson
University, the University of Maryland, Baltimore, and NIAID.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and may be granted unless within fifteen (15) days from the date of
this published notice, the National Insitute of Allergy and Infectious
Diseases receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
Complete license applications submitted in response to this Notice
will be presumed to contain business confidential information and any
release of information in these license applications will be made only
as required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: August 5, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-17214 Filed 8-10-22; 8:45 am]
BILLING CODE 4140-01-P
